Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2007 1
2009 1
2012 1
2015 1
2016 1
2019 2
2020 3
2021 6
2022 4
2023 6
2024 4
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes.
Barry PJ, Mall MA, Álvarez A, Colombo C, de Winter-de Groot KM, Fajac I, McBennett KA, McKone EF, Ramsey BW, Sutharsan S, Taylor-Cousar JL, Tullis E, Ahluwalia N, Jun LS, Moskowitz SM, Prieto-Centurion V, Tian S, Waltz D, Xuan F, Zhang Y, Rowe SM, Polineni D; VX18-445-104 Study Group. Barry PJ, et al. N Engl J Med. 2021 Aug 26;385(9):815-825. doi: 10.1056/NEJMoa2100665. N Engl J Med. 2021. PMID: 34437784 Free PMC article. Clinical Trial.
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.
Keating C, Yonker LM, Vermeulen F, Prais D, Linnemann RW, Trimble A, Kotsimbos T, Mermis J, Braun AT, O'Carroll M, Sutharsan S, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Floreth T, Michelson P, Sosnay PR, Nair N, Zahigian R, Martin H, Ahluwalia N, Lam A, Horsley A; VX20-121-102 Study Group; VX20-121-103 Study Group. Keating C, et al. Lancet Respir Med. 2025 Mar;13(3):256-271. doi: 10.1016/S2213-2600(24)00411-9. Epub 2025 Jan 2. Lancet Respir Med. 2025. PMID: 39756424 Free PMC article. Clinical Trial.
European survey of newborn bloodspot screening for CF: opportunity to address challenges and improve performance.
Munck A, Berger DO, Southern KW, Carducci C, de Winter-de Groot KM, Gartner S, Kashirskaya N, Linnane B, Proesmans M, Sands D, Sommerburg O, Castellani C, Barben J; European CF Society Neonatal Screening Working Group (ECFS NSWG). Munck A, et al. J Cyst Fibros. 2023 May;22(3):484-495. doi: 10.1016/j.jcf.2022.09.012. Epub 2022 Nov 10. J Cyst Fibros. 2023. PMID: 36372700 Free article.
Critical Issues in the Management of CRMS/CFSPID Children: A National Real-World Survey.
Terlizzi V, Fevola C, Presti S, Claut L, Ambroni M, Calderazzo MA, Esposito I, Fabrizzi B, Leonetti G, Lombardo M, Maschio M, Palladino N, Pauro F, Pisi G, Ripani P, Ros M, Rotolo N, Salvatore D, Sepe A, Termini L, Timpano S, Troiani P, Vitullo P, Zanda M, Blasi F, Castellani C. Terlizzi V, et al. Among authors: fabrizzi b. Pediatr Pulmonol. 2025 Jan;60(1):e27483. doi: 10.1002/ppul.27483. Pediatr Pulmonol. 2025. PMID: 39812351 Free PMC article.
Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial.
Durieu I, Clements B, Fabrizzi B, Mall MA, McKone E, Ramsey B, Tullis E, Taylor-Cousar JL, van der Meer R, Bachman E, Chin A, Conner S, Jennings M, Weinstock T, Colombo C, Robinson P. Durieu I, et al. Among authors: fabrizzi b. Am J Respir Crit Care Med. 2025 Oct;211(10):1926-1934. doi: 10.1164/rccm.202411-2312OC. Am J Respir Crit Care Med. 2025. PMID: 40788823 Clinical Trial.
In silico, in vitro and ex vivo characterization of cystic fibrosis transmembrane conductance regulator pathogenic variants localized in the fourth intracellular loop and their rescue by modulators.
Pesce E, Tomati V, Capurro V, Lena M, Pastorino C, Astore M, Kuyucak S, Chevalier B, Sondo E, Cresta F, Dighero A, Terlizzi V, Fevola C, Costa S, Lucanto MC, Daccò V, Claut L, Ficili F, Fabrizzi B, Bocciardi R, Zara F, Castellani C, Galietta LJV, Waters SA, Hinzpeter A, Pedemonte N. Pesce E, et al. Among authors: fabrizzi b. Br J Pharmacol. 2025 Aug 20. doi: 10.1111/bph.70176. Online ahead of print. Br J Pharmacol. 2025. PMID: 40831301
Clinical outcomes of a large cohort of individuals with the F508del/5T;TG12 CFTR genotype.
Tosco A, Castaldo A, Colombo C, Claut L, Carnovale V, Iacotucci P, Lucarelli M, Cimino G, Fabrizzi B, Caporelli N, Majo F, Ciciriello F, Padoan R, Poli P, Taccetti G, Centrone C, Casciaro R, Castellani C, Salvatore D, Colangelo C, Bonomi P, Castaldo G, Terlizzi V. Tosco A, et al. Among authors: fabrizzi b. J Cyst Fibros. 2022 Sep;21(5):850-855. doi: 10.1016/j.jcf.2022.04.020. Epub 2022 May 4. J Cyst Fibros. 2022. PMID: 35523714 Free article.
32 results